Comparative analysis of the therapeutic effects of micro transplantation combined with chemotherapy and simple chemotherapy in the treatment of high-risk myelodysplastic syndrome
微移植联合化疗与单纯化疗治疗较高危骨髓增生异常综合征的疗效比较分析

摘要

目的 观察较高危骨髓增生异常综合征患者采取单一化疗与微移植联合化疗方案的疗效差异。方法 对照组选自本院2019年1月至2022年4月收治较高危骨髓增生异常综合征患者16例，均采取单一化疗。观察组选自本市患者就诊省外其他医院经采取微移植、化疗联合方案治疗后定期在我科门诊随访的患者8例。评价两组临床疗效、造血恢复时间、生存情况。结果 观察组较对照组，前者总有效率提高幅度更为明显（P＜0.05）。对比中性粒细胞恢复时间、血小板恢复时间，观察组较对照组有更为明显减少（P＜0.05）。观察组与对照组比较，其1年、2年的无进展生存期、总生存期均高于对照组（P＜0.05）。结论 较高危骨髓增生异常综合征患者采取微移植、化疗联合方案可明显提升临床疗效，提高生存率。

Abstract

Objective To observe the difference between single chemotherapy and microtransplantation combined chemotherapy in high-risk patients with myelodysplastic syndrome.
Methods Part of the study cases were selected from 16 patients with high-risk myelodysplastic syndrome admitted to our hospital from January 2019 to April 2022 to form the control group, all of whom received single chemotherapy. Observation group 8 patients were selected from other hospitals outside the province who were regularly followed up in our department after microtransplantation and chemotherapy combined treatment. The clinical efficacy, hematopoietic recovery time and survival of the two groups were evaluated.
Results Compared with the control group, the total effective rate of the observation group increased more significantly (P < 0.05). Compared with the control group, the recovery time of neutrophil and platelet was significantly reduced in the observation group (P < 0.05). Compared with the control group, the 1-year and 2-year progression-free survival and overall survival of the observation group were higher than those of the control group (P < 0.05).
Conclusion   The combination of microtransplantation and chemotherapy can significantly improve the clinical efficacy and survival rate of patients with high-risk myelodysplastic syndrome.